Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -1.19%30 Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Island Pharmaceuticals ranks worse than 103626.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Island Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
During the past 5 years, the highest Debt-to-Equity Ratio of Island Pharmaceuticals was 0.80. The lowest was 0.04. And the median was 0.28.
ASX:ILA's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Island Pharmaceuticals (ASX:ILA) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Island Pharmaceuticals Debt-to-Equity Related Terms
Island Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Island Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ILA vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Island Pharmaceuticals (ASX:ILA) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Island Pharmaceuticals and its competitors. Over the past decade, Island Pharmaceuticals' Debt-to-Equity has ranged from 0.04 to 0.80. According to the industry distribution chart, Island Pharmaceuticals ranks #999999 out of 965 companies in the Biotechnology industry.
Is Island Pharmaceuticals' Debt-to-Equity too high?
Island Pharmaceuticals' current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.80. Based on the distribution chart, Island Pharmaceuticals ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #999999 out of 965 companies for Debt-to-Equity. This places Island Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Historically, Island Pharmaceuticals' own Debt-to-Equity has ranged from 0.04 to 0.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score
Get the complete analysis for ASX:ILA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
